Pentwater Capital Management’s RAPT Therapeutics RAPT Stock Holding History

Pentwater Capital Management’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,125	Closed	-$495K	–	158
2022 Q4	$495K	Buy	+3,125	New	+$500K	0.01%	116
2022 Q1	–	Sell	-14,375	Closed	-$4.22M	–	203
2021 Q4	$4.22M	Hold	14,375	–	–	0.05%	103
2021 Q3	$3.57M	Buy	14,375 +1,250	+10%	+$330K	0.04%	120
2021 Q2	$3.34M	Buy	13,125 +9,375	+250%	+$1.75M	0.03%	125
2021 Q1	$666K	Sell	3,750 -1,250	-25%	-$206K	0.01%	254
2020 Q4	$790K	Hold	5,000	–	–	0.01%	174
2020 Q3	$1.29M	Buy	5,000 +438	+10%	+$97.2K	0.02%	146
2020 Q2	$1.06M	Buy	4,562 +153	+3%	+$23.7K	0.02%	102
2020 Q1	$750K	Buy	+4,409	New	+$1M	0.01%	97

Other funds holding RAPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Pentwater Capital Management's RAPT Position: Q1 2023 in Review

Pentwater Capital Management sold out of RAPT Therapeutics (RAPT) in Q1 2023, closing a stake of 3,125 shares — an estimated $495K sold.

Pentwater Capital Management first reported a position in RAPT in Q1 2020 and held it in 9 quarters. The position peaked at $4.22M in Q4 2021. 106 funds tracked by Wall St. Rank hold RAPT as of Q1 2023.

Pentwater Capital Management reported no remaining RAPT Therapeutics position as of Q1 2023 after selling out during the quarter.
Pentwater Capital Management sold 3,125 RAPT Therapeutics shares in Q1 2023, an estimated $495K.
Pentwater Capital Management first reported a position in RAPT Therapeutics in Q1 2020 and held it in 9 quarters.
Pentwater Capital Management's RAPT Therapeutics position peaked at $4.22M in Q4 2021.
106 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2023.

Based on Pentwater Capital Management's 13F filing for Q1 2023, filed 15 May 2023.